Navigation Links
Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
Date:5/14/2009

Ulcerative colitis is a chronic inflammatory bowel disease characterized by inflammation and ulceration of the lining of the colon. Symptoms typically include bloody diarrhea and abdominal pain and in severe cases may require colectomy. According to the Crohn's & Colitis Foundation of America, it is estimated that there are up to approximately 500,000 Americans with ulcerative colitis.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently in Phase 3 clinical trials, the subject of regulatory applications for marketing authorization or approved for commercial sale. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.

Medarex Statement on Cautionary Factors

Except for the historical information presented herein, the statements relating to MDX-1100 in this press release may constitute forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, that are subject to certain risks and uncertainties that could cause actual results to differ materially from any futu
'/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
7. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
8. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
9. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
10. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
11. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 24, 2015  Bayer Corporation hosted its annual "Take Your ... Bayer HealthCare US headquarters.  This is Bayer,s second "Take Your ... Whippany campus, and Thursday,s event welcomed 230 children ... at work. Fortunately, for the kids, this was ... whose mission is "Science For A Better Life," Bayer made ...
(Date:4/24/2015)... , April 24, 2015 In today,s ... employee groups around the world to access diverse ... hours. While there are many areas to misstep ... examine which best practices are necessary and beneficial ... According to research by benchmarking firm, ...
(Date:4/24/2015)... and Markets ( http://www.researchandmarkets.com/research/pmbmv2/global_biobanking ) has announced ... report to their offering. The analysts ... CAGR of 7.07% over the period 2014-2019 ... segments: Equipment and Consumables. This report covers the present ... market for the period 2015-2019. ...
Breaking Medicine Technology:Bayer Hosts "Take Your Child to Work Day" 2Bayer Hosts "Take Your Child to Work Day" 3Bayer Hosts "Take Your Child to Work Day" 4Work Around the Clock: Building Effective Global Capabilities 2Global Biobanking Market Report 2015-2019 - Increase in Strategic Collaborations with Beckman Coulter, Tecan & Thermo Fischer Scientific Dominating 2
... May 2, 2011 NewCardio, Inc., (OTC BB: NWCI) a ... prestigious NYC Bright Lights Conference at the Le Parker Meridien ... of its kind with an exclusive focus on publicly traded ... will present on May 10, 2011 at 9 a.m. ET. ...
... Fla., May 2, 2011 The Unilens Vision Inc. ... of Directors today declared a quarterly cash dividend of $0.045 per ... record at the close of business on May 13, 2011. ... Specialty Contact Lens Company" Established in 1989, Unilens ...
Cached Medicine Technology:NewCardio to Showcase Cardiac Diagnostic Technology at MDB Capital's Bright Lights Conference in New York City on May 10, 2011 2NewCardio to Showcase Cardiac Diagnostic Technology at MDB Capital's Bright Lights Conference in New York City on May 10, 2011 3NewCardio to Showcase Cardiac Diagnostic Technology at MDB Capital's Bright Lights Conference in New York City on May 10, 2011 4Unilens Vision Inc. Declares Quarterly Cash Dividend of $0.045 Per Share 2
(Date:4/27/2015)... April 27, 2015 Healthpointe clinics throughout ... for nail fungi and infections. Onychomycosis, which is commonly ... to 10% of adults in the Western population. This ... in thickness. , Healthpointe’s Anaheim clinic is ... branch dedicated to providing quality skincare products and restorative ...
(Date:4/27/2015)... 2015 Puroast Coffee has signed on to ... The BattleFrog OCR is a series of rigorous courses ... participants in the training that Seals undergo, as well as ... be able to sponsor the BattleFrog events this year,” says ... we find well-suited to give people throughout the country the ...
(Date:4/27/2015)... 27, 2015 The report ... provides comparative analysis on the therapeutic development ... R&D pipelines by identifying new targets and ... Complete report on H1 2015 pipeline review ... tables and 14 figures, spread across 85 ...
(Date:4/27/2015)... Streamwood, IL (PRWEB) April 27, 2015 ... the launch of its brand new website design at ... interactive list of the company’s product catalog, both featured ... n Natural blog ( http://www.purennatural.com/blog/ ). , Pure n ... easy and satisfying shopping experience. The website is neatly ...
(Date:4/27/2015)... Covenant Care, a leading post acute care ... “Enhanced Dining” service with two primary focuses: an ... residents, patients and families to ensure that their preferences ... dining rooms so that they are more homelike, attractive ... our residents is our number one priority and we ...
Breaking Medicine News(10 mins):Health News:Southern California Healthpointe Clinics Now Treating Nail Fungus 2Health News:Puroast Coffee on Tour with BattleFrog 2Health News:Essential Thrombocythemia Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Essential Thrombocythemia Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Essential Thrombocythemia Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4Health News:Pure n Natural Systems, Inc. Launches New Website Design 2Health News:Pure n Natural Systems, Inc. Launches New Website Design 3Health News:Covenant Care Rolls Out "Enhanced Dining" Offering Restaurant Style Experience To Residents, Patients & Families 2
... Calif., Aug. 27 DURECT Corporation,(Nasdaq: DRRX ... PTIE ), its,licensee, has submitted an Investigational New ... Administration (FDA) for an abuse-resistant opioid,pain drug candidate ... third ORADUR-based opioid drug candidate covered by DURECT,s,collaboration ...
... held on September 8, 2008, BURBANK, Calif., Aug. 27 ... will be hosting a Disaster Preparedness,Event sponsored by the National ... focus of this event is to educate older adults,-- 55 ... in an emergency.,Participants will learn how to make a plan, ...
... announced yesterday at a nuclear reactor facility at Petten ... the globe to access and obtain radioactive isotopes, which ... in the United States and worldwide. The shutdown at ... similar shutdown last December of the National Research Universal ...
... WARP Services, LLC, WARP,Robotics, LLP, and Planet Earth ... Delaware and South Carolina Corporation today,announced that the company ... effective 09-02-08 through the month of September., Patrick ... WARP Robotics,LLC a subsidiary of WARP Services, LLC are ...
... NEW YORK, Aug. 27 According to the Fluoride,Action ... parties to restore,scientific integrity to the Centers for Disease ... continued unscientific support for,water fluoridation., "The simplest and ... is,for both Democrats and Republicans to put a commitment ...
... Mutual Insurance Company,(TMIC) said it would appeal to the ... Court of Appeals., The 14th Court rejected Texas ... in Harris County found TMIC acted in bad faith ... The jury also had found,that plaintiff P. Lance Morris ...
Cached Medicine News:Health News:DURECT Announces the IND Submission for a Third Abuse-Resistant Opioid Pain Medication Based on Its ORADUR(TM) Technology 2Health News:DURECT Announces the IND Submission for a Third Abuse-Resistant Opioid Pain Medication Based on Its ORADUR(TM) Technology 3Health News:SNM expresses serious concerns as isotope shortage looms 2Health News:SNM expresses serious concerns as isotope shortage looms 3Health News:Habitat for Humanity and WARP Robotics Team Up 2Health News:Habitat for Humanity and WARP Robotics Team Up 3Health News:Both Parties Need Planks to Restore Scientific Integrity at the CDC 2Health News:Texas Mutual Insurance to Appeal 14th Court's Decision to Texas Supreme Court 2Health News:Texas Mutual Insurance to Appeal 14th Court's Decision to Texas Supreme Court 3Health News:Texas Mutual Insurance to Appeal 14th Court's Decision to Texas Supreme Court 4
Lightweight Pneumatic Conserver., ,NOTE: All models passed the ASTM PS 127-00 regulator ignition safety test....
Lightweight Pneumatic Conserver., ,NOTE: All models passed the ASTM PS 127-00 regulator ignition safety test....
... ,Offers an average 5:1 increase in usage ... use of a standard cannula. , ,The ... offers ambulatory oxygen patients a superior alternative to ... 2-year warranty. , ...
Redesigning the World's Oxygen Therapy One Device at a Time. , ,Everything you like about our OXYMATIC 400 Series conservers, only better!...
Medicine Products: